A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis
-
Published:2024-09
Issue:9
Volume:24
Page:940-941
-
ISSN:1473-3099
-
Container-title:The Lancet Infectious Diseases
-
language:en
-
Short-container-title:The Lancet Infectious Diseases
Author:
Deng Guofang,Fu Liang
Reference8 articles.
1. Streptomycin in pulmonary tuberculosis; report on ten cases;Keers;Lancet,1948
2. Standard therapy for tuberculosis 1985;Snider;Chest,1985
3. Anti-tuberculosis treatment strategies and drug development: challenges and priorities;Dartois;Nat Rev Microbiol,2022
4. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial;Cevik;Lancet Infect Dis,2024
5. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial;Diacon;Lancet,2012